Is neuroendocrine cell differentiation detected using chromogranin a from patients with bone metastatic prostate cancer a prognostic factor for outcome?

Yoshiaki Yamada, Kogenta Nakamura, Shigeyuki Aoki, Tomohiro Taki, Hiroyuki Matsubara, Shotoku Sai, Katsuya Naruse, Motoi Tobiume, Remi Katsuda, Kenji Zennami, Nobuaki Honda, Atsuko Nakagawa, Hiroshi Ikeda

研究成果: ジャーナルへの寄稿学術論文査読

9 被引用数 (Scopus)

抄録

We evaluated the usefulness of overexpression of neuroendrocrine (NE) cell differentiation determined by immunohistochemical staining for chromogranin A (Cg A) in diagnostic needle biopsy specimens of bone metastatic prostate cancers. A total of 50 patients diagnosed as having bone metastatic prostate cancer were studied. The period of observation was between 6.9 and 79.4 months (median 48.7 months). Cg A was detected by immunostaining using the labeled streptavidin biotin method. Cg A-positivity was defined as the presence of immunostained cells in 10% or more of the tumor. All statistical analyses were carried out using the Statistical Package for Social Sciences Software, version 10.0 for Windows. Eleven patients (22%) were classified into the Cg A-positive group. There were no significant differences in clinical data between the Cg A-positive and Cg A-negative groups. The 5-year cause-specific survival rate was 34.1% for the Cg A-positive group and 55.2% for the Cg A-negative group (p=0.3763). The 3-year non-recurrence rate was 9.1% for the Cg A-positive group and 35.9% for the Cg A-negative group, and this difference was significant (p=0.0253). The 3-year cause-specific survival rates after recurrence were 38.4% and 42.3% respectively (p=0.8125). We consider that NE cell differentiation of the primary tumor in cases of bone metastatic prostate cancer is not a prognostic factor for outcome.

本文言語英語
ページ(範囲)1309-1313
ページ数5
ジャーナルOncology reports
15
5
DOI
出版ステータス出版済み - 05-2006
外部発表はい

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「Is neuroendocrine cell differentiation detected using chromogranin a from patients with bone metastatic prostate cancer a prognostic factor for outcome?」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル